ANAB AnaptysBio, Inc

NASDAQ
$48.63

AnaptysBio, Inc (ANAB) is expected to report earnings on December 21, 2026, after the market close. The consensus earnings estimate is $0.37 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.7% since its last earnings release on September 21, 2026.

AnaptysBio Beat Consensus Estimates
Monday, September 21, 2026 · 4:15 PM ET
Earnings Date
3rd Quarter, Sep 2026
Dec 21
Monday · 4:15 PM ET
Earnings Whisper
-
vs $0.37
Rev est $29.57M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $50.91

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About AnaptysBio, Inc

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.